Baxter International Inc
$ 20.63
-2.96%
24 Feb - close price
- Market Cap 10,613,929,000 USD
- Current Price $ 20.63
- High / Low $ 21.41 / 20.57
- Stock P/E N/A
- Book Value 11.92
- EPS -1.75
- Next Earning Report -
- Dividend Per Share $0.52
- Dividend Yield 2.45 %
- Next Dividend Date 2026-04-01
- ROA 0.03 %
- ROE -0.14 %
- 52 Week High 37.25
- 52 Week Low 17.39
About
Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.
Analyst Target Price
$21.63
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-04-30 | 2025-02-13 | 2024-11-08 | 2024-08-06 | 2024-05-02 | 2024-02-08 | 2023-11-02 | 2023-07-27 | 2023-04-27 |
| Reported EPS | 0.44 | 0.69 | 0.59 | 0.55 | 0.58 | 0.49 | 0.68 | 0.65 | 0.88 | 0.68 | 0.55 | 0.59 |
| Estimated EPS | 0.547 | 0.6 | 0.61 | 0.4832 | 0.52 | 0.78 | 0.66 | 0.61 | 0.86 | 0.67 | 0.61 | 0.49 |
| Surprise | -0.107 | 0.09 | -0.02 | 0.0668 | 0.06 | -0.29 | 0.02 | 0.04 | 0.02 | 0.01 | -0.06 | 0.1 |
| Surprise Percentage | -19.5612% | 15% | -3.2787% | 13.8245% | 11.5385% | -37.1795% | 3.0303% | 6.5574% | 2.3256% | 1.4925% | -9.8361% | 20.4082% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-01 | 2026-01-02 | 2025-10-01 | 2025-07-01 | 2025-04-01 | 2025-01-02 | 2024-10-01 | 2024-07-01 | 2024-04-01 | 2024-01-02 |
| Amount | $0.01 | $0.01 | $0.17 | $0.17 | $0.17 | $0.17 | $0.29 | $0.29 | $0.29 | $0.29 |
Next Dividend Records
| Dividend per share (year): | $0.52 |
| Dividend Yield | 2.45% |
| Next Dividend Date | 2026-04-01 |
| Ex-Dividend Date | 2026-02-27 |
Recent News: BAX
2026-02-24 21:55:59
Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue for Q4 CY2025, with sales up 10.9% year-on-year to $393.9 million, surpassing analyst estimates. Both the full-year revenue guidance and adjusted EBITDA also beat expectations, although non-GAAP profit for the quarter slightly missed consensus estimates. The company showed strong operating margin improvement and impressive long-term EPS growth, despite a minor miss on quarterly adjusted EPS.
2026-02-24 20:54:20
The iShares MSCI World ETF (URTH) is preparing for a significant portfolio rebalancing on February 27, 2026, driven by MSCI's latest index review. The fund will add 18 new stocks, including AST SpaceMobile and Coherent Corp, while removing 27, such as DocuSign and Dynatrace. This marks the final adjustment under the current methodology before a revised free-float rounding method is implemented in May 2026.
2026-02-24 20:32:46
The iShares MSCI World ETF (URTH) is set for a major rebalancing on February 27, 2026, driven by MSCI's latest index review. This adjustment will see 18 new stocks, including AST SpaceMobile and Coherent Corp, added to the portfolio, while 27 existing positions, such as DocuSign and Dynatrace, will be removed. This rebalancing is particularly significant as it's the final one under the current methodology before a revised free-float rounding mechanism takes effect in May 2026.
2026-02-24 19:49:50
This article analyzes Baxter International's (BAX) current share price in relation to its underlying value, considering its recent turnaround efforts after years of decline. Using Discounted Cash Flow (DCF) and Price/Sales (P/S) analyses, the article suggests that BAX may be undervalued. It also presents "Bull" and "Bear" case narratives to show how different assumptions about future growth and risks can lead to varying fair value estimates for the company.
2026-02-24 19:49:49
This article analyzes Baxter International's (BAX) share price performance and valuation, noting its recent short-term recovery against a longer-term decline. Using Discounted Cash Flow (DCF) and Price-to-Sales (P/S) methodologies, the analysis suggests BAX is currently undervalued. The article also presents "Narratives" for bull and bear cases, offering different perspectives on the company's future value based on varying assumptions about growth, margins, and risks.
2026-02-24 11:49:51
Cardinal Health's 2026 Biosimilars Report indicates that biosimilars have generated over $56 billion in healthcare savings and are projected to offer up to $181 billion in future savings. The report highlights strong provider confidence, with 99% comfortable explaining biosimilars to patients, and significant advancement in oncology biosimilars achieving 81% market share within five years. Consistent reimbursement is crucial for continued adoption, as nearly 25 new biosimilars are expected to receive FDA approval in various therapeutic areas in the next two years.
